In a real-world setting, the administration of oral semaglutide leads to a significant reduction in the urinary ...

Among patients receiving semaglutide for obesity management, the risk for muscle loss may be higher in older adults and women ...

Polycystic Ovary Syndrome or PCOS affects millions of women in the United States. There is currently no standard treatment for it. Weight loss drugs l ...

People who took semaglutide over a slower, more flexible schedule were significantly less likely to experience nausea and to ...

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

If you’ve been taking Ozempic or Wegovy (both of which contain the active ingredient semaglutide), you might wonder, How long ...

Some health experts view GLP-1s as a promising option for PCOS, which lacks a standard treatment and affects millions of ...

Semaglutide, a popular anti-obesity drug, may come with a hidden cost: significant muscle loss, especially in women and older ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

Older age and female sex may be associated with greater muscle loss in adults with obesity prescribed semaglutide, and ...

GLP-1RA users had a 37% lower risk of developing dementia compared to those on other antidiabetic drugs. Stroke risk reduced ...

GLP-1 receptor agonists semaglutide and tirzepatide are associated with reduced risks of dementia, stroke, and mortality in adults with type 2 diabetes and obesity, new data show.